TP53 and urinary bladder cancer: We previously reported that FKA preferentially inhibits the growth of high-grade, muscle-invasive bladder cancer cell lines (i.e., T24, UMUC3, HT1376, 5637, and HT1197) harboring TP53 mutations; it was more effective on HT1197 and TCCSUP cell lines harboring TP53 mutations in the tetramerization domain over low-grade and p53 wild-type papillary bladder cancer RT4 cells [10].